New Animal Drugs for Use in Animal Feeds; Melengestrol and Lasalocid, 16270-16271 [E7-6180]
Download as PDF
16270
Federal Register / Vol. 72, No. 64 / Wednesday, April 4, 2007 / Rules and Regulations
Commission, Three Lafayette Centre,
1155 21st Street, NW., Washington, DC
20581. Requests for public records
directed to a regional office of the
Commission pursuant to § 145.2 should
be sent to:
Commodity Futures Trading
Commission, 140 Broadway, New York,
New York 10005, Telephone: (646) 746–
9700.
Commodity Futures Trading
Commission, 525 West Monroe Street,
Suite 1100 North, Chicago, Illinois
60661, Telephone: (312) 596–0700.
Commodity Futures Trading
Commission, Two Emanuel Cleaver II
Blvd., Suite 300, Kansas City, Missouri
64112, Telephone: (816) 960–7700.
*
*
*
*
*
Dated: March 29, 2007.
By the Commission.
Eileen A. Donovan,
Acting Secretary of the Commission.
[FR Doc. E7–6190 Filed 4–3–07; 8:45 am]
BILLING CODE 6351–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 520
Oral Dosage Form New Animal Drugs;
Praziquantel and Pyrantel
AGENCY:
Food and Drug Administration,
HHS.
cprice-sewell on PROD1PC61 with RULES
ACTION:
Final rule.
SUMMARY: The Food and Drug
Administration (FDA) is amending the
animal drug regulations to reflect
approval of an original new animal drug
application (NADA) filed by Virbac AH,
Inc. The NADA provides for use of
chewable tablets containing
praziquantel and pyrantel pamoate in
dogs and puppies for the treatment and
control of various internal parasites.
DATES: This rule is effective April 4,
2007.
FOR FURTHER INFORMATION CONTACT:
Melanie R. Berson, Center for Veterinary
Medicine (HFV–110), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 301–827–7540, email: melanie.berson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Virbac
AH, Inc., 3200 Meacham Blvd., Ft.
Worth, TX 76137, filed NADA 141–261
for WORMXPLUS (praziquantel and
pyrantel pamoate) Flavored Chewables
and VIRBANTEL (praziquantel and
pyrantel pamoate) Flavored Chewables
that provides for their use in dogs and
puppies for the treatment and control of
VerDate Aug<31>2005
15:40 Apr 03, 2007
Jkt 211001
various internal parasites. The NADA is
approved as of March 13, 2007, and 21
CFR 520.1871 is amended to reflect the
approval.
In accordance with the freedom of
information provisions of 21 CFR part
20 and 21 CFR 514.11(e)(2)(ii), a
summary of safety and effectiveness
data and information submitted to
support approval of this application
may be seen in the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852, between 9
a.m. and 4 p.m., Monday through
Friday.
Under section 512(c)(2)(F)(ii) of the
Federal Food, Drug, and Cosmetic Act
(the act) (21 U.S.C. 360b(c)(2)(F)(ii)),
this approval qualifies for 3 years of
marketing exclusivity beginning March
13, 2007.
FDA has determined under 21 CFR
25.33(d)(1) that this action is of a type
that does not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
This rule does not meet the definition
of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because
it is a rule of ‘‘particular applicability.’’
Therefore, it is not subject to the
congressional review requirements in 5
U.S.C. 801–808.
List of Subjects in 21 CFR Part 520
Animal drugs.
I Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs and redelegated to
the Center for Veterinary Medicine, 21
CFR part 520 is amended as follows:
PART 520—ORAL DOSAGE FORM
NEW ANIMAL DRUGS
1. The authority citation for 21 CFR
part 520 continues to read as follows:
I
Authority: 21 U.S.C. 360b.
2. Amend § 520.1871 as follows:
a. Revise the section heading and
paragraphs (a) and (b);
I b. Redesignate paragraph (c) as
paragraph (d) and add new paragraph
(c); and
I c. Revise newly redesignated
paragraphs (d)(1)(i), (d)(1)(iii), and
(d)(2).
The revisions, redesignation, and
addition read as follows:
I
I
§ 520.1871
Praziquantel and pyrantel.
(a) Specifications—(1) Each tablet
contains 18.2 milligrams (mg)
praziquantel and 72.6 mg pyrantel (as
pyrantel pamoate).
PO 00000
Frm 00010
Fmt 4700
Sfmt 4700
(2) Each chewable tablet contains 30
mg praziquantel and 30 mg pyrantel
pamoate or 114 mg praziquantel and
114 mg pyrantel pamoate.
(b) Sponsors. See sponsors in
§ 510.600(c) for use as in paragraph (d)
of this chapter.
(1) See No. 000859 for use of tablet
described in paragraph (a)(1) of this
section for use as in paragraph (d)(1) of
this section.
(2) See No. 051311 for use of tablets
described in paragraph (a)(2) of this
section for use as in paragraph (d)(2) of
this section.
(c) Special considerations. See
§ 500.25 of this chapter.
(d) * * *
(1) * * *
(i) Dosage. 1.5 to 1.9 pounds, 1/4
tablet; 2 to 3 pounds, 1/2 tablet; 4 to 8
pounds, 1 tablet; 9 to 12 pounds, 1 1/
2 tablets; 13 to 16 pounds, 2 tablets. If
reinfection occurs, treatment may be
repeated.
*
*
*
*
*
(iii) Limitations. Not for use in kittens
less than 1 month of age or weighing
less than 1.5 pounds. May be given
directly by mouth or in a small amount
of food. Do not withhold food prior to
or after treatment. Consult your
veterinarian before giving to sick or
pregnant animals.
(2) Dogs—(i) Amount. Administer a
minimum dose of 5 mg praziquantel and
5 mg pyrantel pamoate per kilogram
body weight (2.27 mg praziquantel and
2.27 mg pyrantel pamoate per pound
body weight) according to the dosing
tables on labeling.
(ii) Indications for use. For the
treatment and control of roundworms
(Toxocara canis and Toxascaris
leonina), hookworms (Ancylostoma
caninum, Ancylostoma braziliense, and
Uncinaria stenocephala), and
tapeworms (Dipylidium caninum and
Taenia pisiformis) in dogs and puppies.
Dated: March 26, 2007.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. E7–6181 Filed 4–3–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 558
New Animal Drugs for Use in Animal
Feeds; Melengestrol and Lasalocid
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
E:\FR\FM\04APR1.SGM
Final rule.
04APR1
Federal Register / Vol. 72, No. 64 / Wednesday, April 4, 2007 / Rules and Regulations
SUMMARY: The Food and Drug
Administration (FDA) is amending the
animal drug regulations to reflect
approval of an abbreviated new animal
drug application (ANADA) filed by Ivy
Laboratories, Div. of Ivy Animal Health,
Inc. The ANADA provides for use of
single-ingredient Type A medicated
articles containing melengestrol and
lasalocid to make two-way combination
drug Type B or Type C medicated feeds
for heifers fed in confinement for
slaughter.
DATES:
This rule is effective April 4,
List of Subjects in 21 CFR Part 558
Animal drugs, Animal feeds.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs and redelegated to
the Center for Veterinary Medicine, 21
CFR part 558 is amended as follows:
I
PART 558—NEW ANIMAL DRUGS FOR
USE IN ANIMAL FEEDS
1. The authority citation for 21 CFR
part 558 continues to read as follows:
I
2007.
Authority: 21 U.S.C. 360b, 371.
John
K. Harshman, Center for Veterinary
Medicine (HFV–104), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 301–827–0169, email: john.harshman@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Ivy
Laboratories, Div. of Ivy Animal Health,
Inc., 8857 Bond St., Overland Park, KS
66214, filed ANADA 200–451 for use of
HEIFERMAX 500 (melengestrol acetate)
Liquid Premix and BOVATEC (lasalocid
sodium) single-ingredient Type A
medicated articles to make dry and
liquid, two-way combination drug Type
B or Type C medicated feeds for heifers
fed in confinement for slaughter. Ivy
Laboratories’ ANADA 200–451 is
approved as a generic copy of NADA
140–288, sponsored by Pharmacia &
Upjohn Co., a Division of Pfizer, Inc., for
combination use of MGA 500 and
BOVATEC. The application is approved
as of March 12, 2007, and the
regulations are amended in 21 CFR
558.342 to reflect the approval.
In accordance with the freedom of
information provisions of 21 CFR part
20 and 21 CFR 514.11(e)(2)(ii), a
summary of safety and effectiveness
data and information submitted to
support approval of this application
may be seen in the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852, between 9
a.m. and 4 p.m., Monday through
Friday.
The agency has determined under 21
CFR 25.33(a)(2) that this action is of a
type that does not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
This rule does not meet the definition
of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because
it is a rule of ‘‘particular applicability.’’
Therefore, it is not subject to the
congressional review requirements in 5
U.S.C. 801–808.
cprice-sewell on PROD1PC61 with RULES
FOR FURTHER INFORMATION CONTACT:
VerDate Aug<31>2005
15:40 Apr 03, 2007
Jkt 211001
§ 558.342
[Amended]
2. In § 558.342, amend the table in
paragraph (e)(1)(iii) in the ‘‘Sponsor’’
column by adding in numerical
sequence ‘‘021641’’.
I
Dated: March 26, 2007.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. E7–6180 Filed 4–3–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF JUSTICE
Bureau of Prisons
28 CFR Parts 500 and 501
[BOP–1116; AG Order No. 2878–2007]
RIN 1120–AB08
National Security; Prevention of Acts
of Violence and Terrorism
Bureau of Prisons, Department
of Justice.
ACTION: Final rule.
AGENCY:
SUMMARY: This rule finalizes the interim
rules on Special Administrative
Measures that were published on
October 31, 2001 (66 FR 55062). The
previously existing regulations
authorized the Bureau of Prisons
(Bureau), at the direction of the
Attorney General, to impose special
administrative measures with respect to
specified inmates, based on information
provided by senior intelligence or law
enforcement officials, if determined
necessary to prevent the dissemination
of either classified information that
could endanger the national security, or
of other information that could lead to
acts of violence and/or terrorism. The
interim rule extended the period of time
for which such special administrative
measures may be imposed from 120
days to up to one year, and modified the
standards for approving extensions of
such special administrative measures. In
addition, where the Attorney General
PO 00000
Frm 00011
Fmt 4700
Sfmt 4700
16271
has certified that reasonable suspicion
exists to believe that an inmate may use
communications with attorneys (or
agents traditionally covered by the
attorney-client privilege) to further or
facilitate acts of violence and/or
terrorism, the interim rule amended the
previously existing regulations to
provide that the Bureau must provide
appropriate procedures to monitor or
review such communications to deter
such acts, subject to specific procedural
safeguards, to the extent permitted
under the Constitution and laws of the
United States. The interim rule also
requires the Director of the Bureau of
Prisons to give written notice to the
inmate and attorneys and/or agents
before monitoring or reviewing any
communications as described in this
rule. The interim rule also provided that
the head of each component of the
Department of Justice that has custody
of persons for whom special
administrative measures are determined
to be necessary may exercise the same
authority to impose such measures as
the Director of the Bureau of Prisons.
DATES: Effective date: June 4, 2007.
ADDRESSES: Rules Unit, Office of the
General Counsel, Bureau of Prisons, 320
First Street, NW., Washington, DC
20534.
FOR FURTHER INFORMATION CONTACT:
Sarah Qureshi, Office of the General
Counsel, Bureau of Prisons, (202) 307–
2105.
SUPPLEMENTARY INFORMATION: This rule
finalizes interim rules on Special
Administrative Measures that were
published on October 31, 2001 (66 FR
55062). These rules are codified at 28
CFR 501.2 (national security) and 501.3
(violence and terrorism). We received
approximately 5000 comments in
opposition to the rule, which we discuss
below.
Section 501.2
Section 501.2 authorizes the Director
of the Bureau, at the direction of the
Attorney General, to impose special
administrative measures with respect to
a particular inmate that are reasonably
necessary to prevent disclosure of
classified information. These
procedures may be implemented after
written certification by the head of a
United States intelligence agency that
the unauthorized disclosure of such
information would pose a threat to the
national security and that there is a
danger that the inmate will disclose
such information. These special
administrative measures ordinarily may
include housing the inmate in special
housing units and/or limiting certain
privileges, including, but not limited to,
E:\FR\FM\04APR1.SGM
04APR1
Agencies
[Federal Register Volume 72, Number 64 (Wednesday, April 4, 2007)]
[Rules and Regulations]
[Pages 16270-16271]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-6180]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 558
New Animal Drugs for Use in Animal Feeds; Melengestrol and
Lasalocid
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
-----------------------------------------------------------------------
[[Page 16271]]
SUMMARY: The Food and Drug Administration (FDA) is amending the animal
drug regulations to reflect approval of an abbreviated new animal drug
application (ANADA) filed by Ivy Laboratories, Div. of Ivy Animal
Health, Inc. The ANADA provides for use of single-ingredient Type A
medicated articles containing melengestrol and lasalocid to make two-
way combination drug Type B or Type C medicated feeds for heifers fed
in confinement for slaughter.
DATES: This rule is effective April 4, 2007.
FOR FURTHER INFORMATION CONTACT: John K. Harshman, Center for
Veterinary Medicine (HFV-104), Food and Drug Administration, 7500
Standish Pl., Rockville, MD 20855, 301-827-0169, e-mail:
john.harshman@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Ivy Laboratories, Div. of Ivy Animal Health,
Inc., 8857 Bond St., Overland Park, KS 66214, filed ANADA 200-451 for
use of HEIFERMAX 500 (melengestrol acetate) Liquid Premix and BOVATEC
(lasalocid sodium) single-ingredient Type A medicated articles to make
dry and liquid, two-way combination drug Type B or Type C medicated
feeds for heifers fed in confinement for slaughter. Ivy Laboratories'
ANADA 200-451 is approved as a generic copy of NADA 140-288, sponsored
by Pharmacia & Upjohn Co., a Division of Pfizer, Inc., for combination
use of MGA 500 and BOVATEC. The application is approved as of March 12,
2007, and the regulations are amended in 21 CFR 558.342 to reflect the
approval.
In accordance with the freedom of information provisions of 21 CFR
part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and
effectiveness data and information submitted to support approval of
this application may be seen in the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
The agency has determined under 21 CFR 25.33(a)(2) that this action
is of a type that does not individually or cumulatively have a
significant effect on the human environment. Therefore, neither an
environmental assessment nor an environmental impact statement is
required.
This rule does not meet the definition of ``rule'' in 5 U.S.C.
804(3)(A) because it is a rule of ``particular applicability.''
Therefore, it is not subject to the congressional review requirements
in 5 U.S.C. 801-808.
List of Subjects in 21 CFR Part 558
Animal drugs, Animal feeds.
0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs and
redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is
amended as follows:
PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
0
1. The authority citation for 21 CFR part 558 continues to read as
follows:
Authority: 21 U.S.C. 360b, 371.
Sec. 558.342 [Amended]
0
2. In Sec. 558.342, amend the table in paragraph (e)(1)(iii) in the
``Sponsor'' column by adding in numerical sequence ``021641''.
Dated: March 26, 2007.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. E7-6180 Filed 4-3-07; 8:45 am]
BILLING CODE 4160-01-S